# reload+after+2024-01-21 14:43:52.864756
address1§2929 Arch Street
address2§Suite 600
city§Philadelphia
state§PA
zip§19104
country§United States
phone§267 759 3100
website§https://www.cabalettabio.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; CABA-201, a 4-1BB-containing CD19-CAR T investigational therapy, for the treatment of severe autoimmune diseases; PLA2R-CAART, a discovery stage product to treat patients with PLA2R-associated membranous nephropathy; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
fullTimeEmployees§92
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Steven A. Nichtberger M.D.', 'age': 62, 'title': 'Co-Founder, Chairman, CEO & President', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 970596, 'exercisedValue': 0, 'unexercisedValue': 3428895}, {'maxAge': 1, 'name': 'Dr. Gwendolyn K. Binder Ph.D.', 'age': 48, 'title': 'President of Science & Technology', 'yearBorn': 1975, 'fiscalYear': 2022, 'totalPay': 692988, 'exercisedValue': 0, 'unexercisedValue': 1736629}, {'maxAge': 1, 'name': 'Dr. David J. Chang FACR, M.D., M.P.H.', 'age': 60, 'title': 'Chief Medical Officer', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 676740, 'exercisedValue': 0, 'unexercisedValue': 479360}, {'maxAge': 1, 'name': 'Dr. Michael C. Milone M.D., Ph.D.', 'title': 'Co-Founder & Co-Chair of Scientific Advisory Board', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Aimee  Payne M.D., Ph.D.', 'title': 'Co-Founder & Co-Chair of Scientific Advisory Board', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Anup  Marda M.B.A.', 'age': 46, 'title': 'Chief Financial Officer', 'yearBorn': 1977, 'fiscalYear': 2022, 'totalPay': 548197, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Samik  Basu M.D.', 'title': 'Chief Scientific Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Michael  Gerard J.D.', 'age': 43, 'title': 'General Counsel & Secretary', 'yearBorn': 1980, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Heather  Harte-Hall M.Sc.', 'title': 'Chief Compliance Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': "Ms. Martha  O'Connor", 'title': 'Chief Human Resources Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§6
boardRisk§9
compensationRisk§8
shareHolderRightsRisk§10
overallRisk§10
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§2.479
currency§USD
dateShortInterest§1702598400
forwardEps§-1.76
exchange§NMS
quoteType§EQUITY
shortName§Cabaletta Bio, Inc.
longName§Cabaletta Bio, Inc.
firstTradeDateEpochUtc§1572010200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§6fe46e50-561f-3aea-a102-2503a6e5bebe
gmtOffSetMilliseconds§-18000000
targetHighPrice§50.0
targetLowPrice§18.0
targetMeanPrice§32.0
targetMedianPrice§31.0
recommendationMean§1.6
recommendationKey§buy
numberOfAnalystOpinions§7
quickRatio§15.485
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
